RxDoctor Payments Data

John Bedotto, MD

Interventional Cardiology · Las Vegas, NVNPI 1164468385

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,939 of the $19,994 with a category attached, or 79.7%. 14 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 55.4% of the total. Reporting peaked in 2019 at $18,338 and has fallen 99.5% since, to $90 in 2024.

$19,994in general payments, 2019–2025

Across 46 payments — averaging $434.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$11K
  • Sanofi-aventis U.S. LLC$7K
  • Amgen$938
  • Akcea Therapeutics, Inc.$380
  • Atricure, Inc.$156
  • E.r. Squibb & Sons, L.L.C.$120
  • plus $531 from 8 others

What the payments were for

  • Speaking & faculty fees$15,93980%
  • Travel & lodging$1,1786%
  • Food & beverage$2,07410%
  • Education$8044%

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,994 in reported general payments places this provider in the 75th percentile of 62 interventional cardiology providers in Nevada.

See all interventional cardiology providers in Nevada

Medicare billing

Part B allowed, 2024
$132,205
Medicare patients
684
Services billed
1,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban343$516,153
Repatha SureclickEvolocumab151$175,849
XareltoRivaroxaban86$93,600
EntrestoSacubitril/Valsartan65$90,740
VascepaIcosapent Ethyl28$29,764
MultaqDronedarone Hcl13$20,048
Praluent PenAlirocumab18$18,527
Ezetimibe433$12,558
Atorvastatin Calcium706$6,623
Metoprolol Succinate407$5,811
Rosuvastatin Calcium351$5,309
Irbesartan242$4,438
Nebivolol Hcl43$4,259
Ranolazine ErRanolazine25$3,087
Amlodipine Besylate448$3,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$107$516,153343 claims
NovartisEntresto$28$90,74065 claims
Sanofi-aventis U.S. LLCMultaq$6,790$20,04813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 62 interventional cardiology providers in Nevada.

Other interventional cardiology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →